Patent intelligence · WO
WO 2024094673
RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH
RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH
Patent details — WO 2024094673
- Jurisdiction
- WO
- Status
- granted
- Grant date
- May 10, 2024
- Expiration
- May 5, 2044
- Applicant
- ASCENDIS PHARMA BONE DISEASES AS [DK]
- CPC classes
- A61K 38/ 29 A I, A61K 47/ 60 A I, A61K/3829, A61K/4760
Quick answer
WO 2024094673 (RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH) is held by ASCENDIS PHARMA BONE DISEASES AS [DK]. Status: granted. Granted May 10, 2024. Expires May 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASCENDIS PHARMA BONE DISEASES AS [DK]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 29 A I, A61K 47/ 60 A I, A61K/3829, A61K/4760, A61K/90019, A61P 5/ 18 A I
More from ASCENDIS PHARMA BONE DISEASES AS [DK]
Related pharmaceutical patents in our USPTO index.
-
WO 2025051711
TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE
granted -
US 2023321198
Dosage Regimen for a Controlled-Release PTH Compound
granted -
CA 3230895
TRAITEMENTS AVEC DES COMPOSES PTH A ACTION PROLONGEE
granted -
CA 3192772
AMELIORATION DU BIEN-ETRE PHYSIQUE ET MENTAL DE PATIENTS ATTEINTS D'HYPOPARATHYROIDISME
granted -
CA 3161101
TRAITEMENT DE L'HYPOPARATHYROIDISME
granted -
US 2020276276
PTH Prodrugs
granted -
CA 3129357
FORMULATIONS PHARMACEUTIQUES LIQUIDES DE CONJUGUES PTH
granted
Frequently asked questions
What is US patent 2024094673?
WO 2024094673 (RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH) is held by ASCENDIS PHARMA BONE DISEASES AS [DK]. Status: granted. Granted May 10, 2024. Expires May 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2024094673?
ASCENDIS PHARMA BONE DISEASES AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does WO 2024094673 expire?
Our index shows an expiration date of May 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.